Compare Inovio Pharmaceuticals Inc (INO) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs ProShares Ultra QQQ ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $0.8 (market cap $78.55M), while ProShares Ultra QQQ ETF trades at $91.99. The key difference: ProShares Ultra QQQ ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | QLD | |
|---|---|---|
Market Cap | $78.55M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $2.87 | $100.53 |
52-Week Low | $0.66 | $57.16 |
Enterprise Value | $49.56M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
QLD, the ProShares Ultra QQQ ETF, trades at $92.32, up 0.75% today, reflecting a bullish technical stance with moving averages signaling strength. The fund offers 2x daily leveraged exposure to the Nasdaq-100 index, having delivered over 10,000% total return since inception. Recent institutional buying includes 180 Wealth Advisors increasing its stake by 29.4% in Q2 2026 (SEC Form 13F filing, August 6, 2026).
Outlook remains tied to tech sector performance, with AI optimism and easing geopolitical tensions cited as tailwinds (Zacks Investment Research, May 29, 2026). Key risks include leveraged ETF decay and volatility, evidenced by a 63.80% historical maximum drawdown. The neutral oscillator reading suggests near-term consolidation may precede further moves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
